230 results on '"Kamusheva, Maria"'
Search Results
52. COVID-19 pandemic impact on the pharmaceutical sector in Bulgaria
53. Do Advanced Therapies Have a Future in the Low- and Middle-Income Countries - The Case of Bulgaria, Romania, and Poland
54. Review of medicine utilization for Parkinson’s disease management: the Bulgarian perspective
55. Social and economic burden of breast cancer in the North East region of Bulgaria
56. Pharmacotherapeutic Patterns and Patients’ Access to Pharmacotherapy for Some Rare Diseases in Bulgaria – A Pilot Comparative Study
57. Do We Need a Specific Guideline for Assessment and Improvement of Acromegaly Patients Adherence?
58. A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care
59. A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care
60. Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries
61. Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
62. Clinical and economic assessment of nusinersen: the Bulgarian perspective
63. A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care
64. Influence of COVID-19 on Health-Related Quality of Life and the Perception of Being Vaccinated to Prevent COVID-19: An Approach for Community Pharmacists from Romania and Bulgaria
65. Volume and trends of adalimumab and pembrolizumab reimbursed market: the Bulgarian perspective
66. Screening for depression among chronically ill patients in community pharmacy settings: a pilot study in Bulgaria
67. Pharmacoeconomic analysis of pertussis booster dose in adolescents in Bulgaria
68. Evaluation of Quality of Life after Implantation of Light or Standard Polypropylene Hernia Meshes.
69. Clinical and economic assessment of nusinersen: the Bulgarian perspective
70. Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria
71. New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria
72. Cardiovascular co-morbidity in patients with COPD in Bulgaria
73. Analysis of patients' access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece.
74. Additional file 1: of The European challenges of funding orphan medicinal products
75. Chronic obstructive pulmonary disease exacerbations and progression in relation to ambient air pollutants exposure
76. Incretins and SGLT-2i Therapy of Type 2 Diabetes – Real Life Study of Their Therapeutic and Economic Effects
77. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria
78. Costs and outcomes for individuals with psychosis prior to hospital admission and following discharge in Bulgaria
79. Pilot Study on the Cost of Some Oncohematology Diseases in Bulgaria
80. Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA
81. Cost-effectiveness analysis of current treatment of individuals with acute exacerbation of schizophrenia in Bulgaria
82. Micro and macro analysis on the burden of COPD hospitalizations on the Bulgarian healthcare system
83. Improved quality of diabetes control reduces complication costs in Bulgaria
84. Economic and pharmaco-economic analysis of acromegaly treatment: a systematic review
85. Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis
86. Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
87. Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines
88. An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries
89. Polycystic ovary syndrome impact on women's quality of life: pilot study
90. A one-way, static Markov model estimating the social and economic burden of chronic obstructive pulmonary disease in Bulgaria for patients who smoke or don't
91. Screening and diagnosis of chronic HCV infection in Bulgaria: A review of the current practice
92. A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria
93. Orphan medicinal products’ access to the Bulgarian pharmaceutical market – challenges and obstacles
94. Inhaled corticosteroids in stable COPD – international recommendations and reality in Bulgaria
95. Evaluation of the economic and social burden of chronic obstructive pulmonary disease (COPD)
96. Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy
97. Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria
98. Efficacy and Safety of Reimbursed Orphan Medicines in Bulgaria – Systematic Review and Meta-analysis (Part I)
99. Psoriasis as a multisystem disease - cost of illness analysis
100. Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.